Navigation Links
New Clinical Study News for Treatment of Sinusitis, Sinus Infection and Allergy Sufferers Now Have a New Effective Form of Relief through Sinus Dynamics

This exciting clinical study news is the best news that we have been waiting on for the past four years to prove the deposition of the medication through Sinus Dynamics.

WESTLAKE VILLAGE, Calif., March 23 /PRNewswire/ -- Most ENTs and physicians who have prescribed Sinus Dynamics have always asked if it would be better to have a clinical study done on the amount of medication deposited and penetrated into the sinuses. Now this fantastic news and clinical study proves the SINUS DYNAMICS treatment to be 82.9% successful for treatment of pre-sinus surgery, post-sinus surgery, acute and chronic sinusitis.

I encourage everyone to please spend a few minutes to read the attached study and familiarize yourself with the facts in the study. After reading the study, I am sure you will be able to better understand why Sinus Dynamics treatment is very effective treatment compared to any other treatments (Sinus Wash, Sinus Spray, oral Antibiotics and medications) for sinusitis. Now you can share this great news with everyone who has sinusitis or sinus infections and needs fast and proven treatment to overcome their sinusitis and sinus infection problems for good.

As you read this study, it will show you that Sinus Dynamics has the smallest particle size in the industry and is able to deposit the medicine into the sinuses better than any other sinusitis or sinus infection products without any side effects. Also in order to have the best result in TOPICAL treatment of sinusitis, you need to have the particle size of 3.2 mmhg and Sinus Dynamics is the ONLY treatment that meets this requirement.

The comprehensive study was published in August of 2008 and was conducted by clinical research physicians who are on staff with three prominent American medical universities. When compared to any other aerosolized therapies available in the medical industry, the study fully confirms that the smaller size of the mist particle of the Sinus Dynamics SinusAero Nebulizer penetrates the ostium for achieving topical deposition of medications on the mucosa of the paranasal sinus cavities; including the hard-to-reach maxillary sinus. Additionally, the study discusses the fact that the deposition of the medication on the sinus lining was the same whether or not the patient had a FESS procedure (FESS stands for Functional Endoscopic Sinus Surgery). The study also discussed that the rate of recovery from the patient's acute or chronic sinusitis was the same using the Sinus Dynamics therapy for patients who had FESS procedures performed on them, and for those who did not. Please see the last paragraph on page one of the study where Sinus Dynamics is mentioned.

The Sinus Dynamics program is a unique form of treatment.

Please check the testimonials on

Sinus Dynamics works with most insurance companies and will handle the prescription from when it is received through handling all insurance relations. Select antibiotics, anti-fungals and anti-inflammatories are also offered to help relieve patients of their symptoms of sinusitis and allergies. Sinus Dynamics can be visited on the web at or reached toll free at 877-447-4276.

This press release was issued through For further information, visit

SOURCE Sinus Dynamics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Herbalife Protein Shake Proven Effective in Clinical Study
2. Latest Osteoporosis Research Translated for Health Professionals to Use in Clinical Setting
3. Former Merck Executive Joins Board of Clinical Information Network, Inc.
4. New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics
5. Conflicts of interest in clinical research
6. Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial
7. Clinical Data from Plastic Surgeon in New Jersey Helped in Final Determination of 2008's Top Plastic Surgery Procedures
8. EAU launches new clinical guidelines for 2009 -- kidney cancer
9. New Clinical Study Finds Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Accurate in the Noninvasive Monitoring of Fluid Status During Surgery
10. Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings
11. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
Post Your Comments:
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... ... , ... Jobs in hospital medical laboratories and in the imaging field lead ... Aureus Medical Group . These fields, as well as travel nursing, ... healthcare jobs through the company’s website, , The leading healthcare staffing ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast ... found on mammography, according to a study published online in the journal Radiology. ... on mammography may necessitate a change in treatment. , Breast MRI is the ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
Breaking Medicine Technology: